Department of Pharmacy, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032, PR China.
J Microbiol. 2010 Apr;48(2):223-8. doi: 10.1007/s12275-009-0233-4. Epub 2010 May 1.
A multivalent fusion vaccine is a promising option for protection against Helicobacter pylori infection. In this study, UreB414 was identified as an antigenic fragment of urease B subunit (UreB) and it induced an antibody inhibiting urease activity. Immunization with UreB414 partially protected mice from H. pylori infection. Furthermore, a trivalent fusion vaccine was constructed by genetically linking heat shock protein A (HspA), H. pylori adhesin A (HpaA), and UreB414, resulting in recombinant HspA-HpaA-UreB414 (rHHU). Its protective effect against H. pylori infection was tested in BALB/c mice. Oral administration of rHHU significantly protected mice from H. pylori infection, which was associated with H. pylori-specific antibody production and Th1/Th2-type immune responses. The results show that a trivalent fusion vaccine efficiently combats H. pylori infection, and that an antigenic fragment of the protein can be used instead of the whole protein to construct a multivalent vaccine.
一种多价融合疫苗是预防幽门螺杆菌感染的有希望的选择。在这项研究中，UreB414 被鉴定为尿素酶 B 亚单位 (UreB) 的抗原片段，它诱导了一种抑制尿素酶活性的抗体。用 UreB414 免疫可部分保护小鼠免受幽门螺杆菌感染。此外，通过基因连接热休克蛋白 A (HspA)、幽门螺杆菌黏附素 A (HpaA) 和 UreB414 构建了一种三价融合疫苗，导致重组 HspA-HpaA-UreB414(rHHU)。在 BALB/c 小鼠中测试了其对幽门螺杆菌感染的保护作用。rHHU 的口服给药可显著保护小鼠免受幽门螺杆菌感染，这与幽门螺杆菌特异性抗体的产生和 Th1/Th2 型免疫反应有关。结果表明，三价融合疫苗能有效对抗幽门螺杆菌感染，并且蛋白质的抗原片段可用于替代整个蛋白质来构建多价疫苗。
